Savara (SVRA) Provides Pipeline and Business Update

Go back to Savara (SVRA) Provides Pipeline and Business Update

Savara Provides Pipeline and Business Update

December 10, 2020 8:05 AM EST

Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc

Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO

Reduces Operating Expenses to Align with Streamlined Development Programs

Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex in aPAP

Revises Study-Start Guidance for IMPALA 2 Clinical Trial to Q2 2021

AUSTIN, Texas--(BUSINESS... More